Lv3
214 积分 2020-12-07 加入
CDK4 and CDK6 kinases: From basic science to cancer therapy
14天前
已完结
Determination of Unbound Partition Coefficient and in Vitro–in Vivo Extrapolation for SLC13A Transporter–Mediated Uptake
22天前
已完结
Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer
27天前
已关闭
KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy
1个月前
已完结
Focal Adhesion Regulation as a Strategy against Kidney Fibrosis
2个月前
已完结
In-depth Evaluation of the Olink Target 48 Cytokine Panel: Inter-Laboratory Evaluation of Performance and Reliability for Biomarker Studies in Oncology
3个月前
已关闭
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
3个月前
已完结
A neomorphic protein interface catalyzes covalent inhibition of RAS G12D aspartic acid in tumors
4个月前
已完结
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
4个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
4个月前
已完结
皖公网安备34019202002308
